We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metabolomics Analysis Method Used for Diagnosis of IBD

By LabMedica International staff writers
Posted on 15 Jul 2019
A team of Canadian researchers used an advanced metabolomics approach to differentiate inflammatory bowel syndrome (IBS) from other related gastrointestinal disorders.

Irritable bowel syndrome (IBS), the most commonly diagnosed functional gastrointestinal (GI) disorder in developed countries, is characterized by chronic abdominal pain and altered bowel habits. More...
Accurate and timely diagnosis of IBS is challenging as it relies on observation of symptoms and an evolving set of exclusion criteria to distinguish it from other related GI disorders such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis.

To develop better a better method for diagnosis of IBS, investigators at McMaster University (Montreal, Canada) used multisegment injection-capillary electrophoresis-mass spectrometry to generate metabolite profiles in repeat urine specimens collected from a cohort of 42 IBS patients and compared them to profiles from 20 healthy controls.

Results revealed ten consistently elevated urinary metabolites in repeat samples collected from IBS patients at two different time points, which were associated with greater collagen degradation and intestinal mucosal turn-over processes likely due to low-grade inflammation. IBS-specific metabolites identified in urine included a series of hydroxylysine metabolites (O-glycosylgalactosyl-hydroxylysine, O-galactosyl-hydroxylysine, lysine), mannopyranosy-l-tryptophan, imidazole propionate, glutamine, serine, ornithine, dimethylglycine, and dimethylguanosine.

While the metabolomics approach avoided invasive blood sampling, colonoscopy, and/or tissue biopsies, the investigators warned that at this time its usefulness was limited somewhat by the propensity of IBS patients to suffer from additional illnesses, including depression, and that they took more prescribed medications than did the healthy controls.

“Diagnostic testing for IBS involves a long process of excluding other related gut disorders, such as inflammatory bowel disease,” said senior author Dr. Philip Britz-McKibbin, professor of chemistry and chemical biology at McMaster University.

"We were interested in finding if there is a better way to detect and monitor IBS that avoids invasive colonoscopy procedures while also giving us better insights into its underlying mechanisms.”

The study was published in the May 20, 2019, online edition of the journal Metabolomics.

Related Links:
McMaster University


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.